Year-end Sale % OFF 
Abstract
Pegylated-interferon alpha (Peg-IFN α) is the therapy most commonly used to treat chronic hepatitis delta virus (HDV) infection. In the present study, we planned to investigate effect of IL28B polymorphism on response to Peg-IFN α therapy and disease progression in patients with chronic HDV. A total of 47 patients who received Peg-IFNα therapy for at least one year were investigated. The patients were divided into three groups based on their response to treatment: sustained viral response (SVR) (32%), unresponsive (53%), and relapse (15%). The groups were compared in terms of age, gender, blood biochemistry (albumin, total bilirubin, lactic acid dehydrogenase, ALT, AST, ALP, GGT), complete blood count, HBeAg, HBsAg, HBV-DNA, HDV-RNA, IL28B genotypes (CC, CT, TT), and results of liver biopsy. Regarding the investigation of IL28B genotype, the prevalence of CC, CT, and TT showed no difference among the three groups. In the SVR group, the prevalence of CC was 53%, CT was 47%, but there was no patient with TT. In the unresponsive group, prevalence of CC was 52%, CT was 32%, and TT was 16%. In the relapse group, prevalence of CC was 43%, CT was 57%, but there was no patient with TT genotype. No significant difference was found among the groups with sustained response, no response, and relapse in terms of CC and CT polymorphisms (p>0.05). No relationship was found between IL28B rs12979860 polymorphism and response to treatment and disease severity in patients with chronic HDV infection.
Highlights
IntroductionHepatitis delta virus (HDV) infection is widely distributed all over the world. It is believed that about 15 million people are infected with hepatitis delta virus (HDV) [1]
Pegylated-interferon alpha (Peg-IFN α) is the therapy most commonly used to treat chronic hepatitis delta virus (HDV) infection
The baseline mean liver fibrosis score and mean histological activity index (HAI), prevalence of HBeAg positivity, and the mean HDV-RNA levels were compared between the patients with different genotypes, no difference was determined between the groups
Summary
Hepatitis delta virus (HDV) infection is widely distributed all over the world. It is believed that about 15 million people are infected with HDV [1]. Pegylated-interferon alpha (Peg-IFN α) is currently used in the treatment of chronic delta hepatitis with a sustained virological response rate ranging between 20% and 40% [10,11]. To investigate the relationship between interleukin-28B polymorphism and response to Peg-IFN α therapy and disease severity in patients treated for chronic delta hepatitis. Relapse was defined as obtaining virological response at the end of treatment but HDV-RNA becoming positive again after discontinuation of therapy. Statistical analysis revealed no significant difference among the SVR group, the un responsive group, and the relapse group in terms of prevalence of IL28B rs12979860 genotypes (Table 4). The baseline mean liver fibrosis score and mean histological activity index (HAI), prevalence of HBeAg positivity, and the mean HDV-RNA levels were compared between the patients with different genotypes, no difference was determined between the groups.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
